Cellebrite DI

CLBT · NASDAQ

$11.37+$0.225 (+2.02%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $11.15

CLBT analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 10 analysts

Average $16.31 (+43.4% upside)

Low: $12.63
Now: $11.37
High: $21.43

Upgrades and downgrades

The latest rating actions, newest first

CLBT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
DA Davidson	Sep 15, 2026	Maintains	Buy	$15.00	61%
Lake Street	Aug 14, 2026	Maintains	Buy	$21.00 → $15.00	48%
JP Morgan	Aug 14, 2026	Maintains	Overweight	$20.00 → $16.00	58%
DA Davidson	Aug 14, 2026	Maintains	Buy	$22.00 → $15.00	61%
Needham	Aug 14, 2026	Maintains	Buy	$15.00 → $12.50	63%
DA Davidson	Aug 6, 2026	Maintains	Buy	$20.00 → $22.00	61%
DA Davidson	May 27, 2026	Initiates	Buy	$20.00	61%
Needham	May 15, 2026	Maintains	Buy	$18.00 → $15.00	63%
Needham	Feb 12, 2026	Maintains	Buy	$24.00 → $18.00	63%
JP Morgan	Nov 13, 2025	Maintains	Overweight	$23.00 → $24.00	58%

The case for and against

Updated Oct 18, 2026

Bull case

Cellebrite DI is supported by resilient demand in Defense & Intelligence, where ARR grew 25% Y/Y in Q2 and management highlighted strong interest in offline, edge-enabled mobile intelligence tools, including the new C-Tek and drone-extraction capabilities. Its broader fundamentals remain attractive because Q2 revenue rose 16% Y/Y to $131.1 million, gross margin reached 85.5%, and adjusted EBITDA was $31.8 million, while EBITDA guidance was raised to $153 million to $159 million despite softer ARR guidance. The company also has meaningful upside from Genesis, with more than half a dozen Q2 deals, about $400K of ARR secured after June 10th, and ARR approaching $1 million, suggesting new products can offset slower legacy migrations and improve long-term profitability.

Bear case

Cellebrite DI is exposed to an unusually concentrated public-sector revenue base, with about 90% of revenue tied to law enforcement and government customers and U.S. federal representing a high-teens share, making results vulnerable to budget delays, shutdowns, procurement friction, and shifting spending priorities. Its recent ARR shortfall and lowered CY26 revenue and ARR guidance underscore execution risk, as several large deals slipped by about 6 weeks amid foreign filer and data-sovereignty requirements, while Inseyets conversion is only at 65% with a lower-than-expected uplift. Growth also looks less durable because the company must continuously keep pace with changing hardware and OS security, while any successful patching of vulnerabilities by Apple or Android could erode its core device-unlock value proposition and pressure future results.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.